Ernexa Therapeutics (ERNA) News
NASDAQ: ERNAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ERNA news summary
We found 3 recent headlines mentioning Ernexa Therapeutics (ERNA): 1 in the past week and 1 in the past 30 days, most often from GlobeNewswire, Nasdaq. ERNA is making an outsized move today, down 16.56% at $1.36, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Ernexa Therapeutics Inc. Approves $5,000 Monthly Cash Compensation for CFO Mark J. Keeley", was published by Nasdaq on Nov 19, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Ernexa Therapeutics headlines
- Ernexa Therapeutics Inc. Approves $5,000 Monthly Cash Compensation for CFO Mark J. KeeleyOn November 14, 2026, the Board of Directors of Ernexa Therapeutics Inc. approved a Consulting Agreement Addendum, effective November 9, 2026, to the Consulting Agreement, dated August 10, 2026, by…Nasdaq
- Ernexa Therapeutics Highlights ERNA-101’s Path Toward the Clinic and Differentiated Cell Therapy Platform in New “What This Means” SegmentLeadership discusses recent FDA engagement, the technology underlying ERNA-101 and the development strategy supporting planned first-in-human clinical evaluationGlobeNewswire
- Ernexa Therapeutics to Participate in Virtual Investor Closing Bell SeriesLive video webcast with Sanjeev Luther, President and Chief Executive Officer; Dr. Christopher Rohde, developer of the technology underlying Ernexa’s platform and member of Ernexa’s Scientific…GlobeNewswire